Kura Oncology Inc. (NASDAQ:KURA) fell 1.8% during mid-day trading on Thursday . The stock traded as low as $4.20 and last traded at $4.27, with a volume of 100,140 shares traded. The stock had previously closed at $4.35.

A number of research analysts recently issued reports on the company. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 17th.

The company’s market capitalization is $79.66 million. The company’s 50-day moving average is $3.23 and its 200 day moving average is $3.85.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, May 11th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Equities analysts predict that Kura Oncology Inc. will post ($1.70) EPS for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.